Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-7066
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
ABBV-7066 is an investigational fixed-dose combination therapy being developed by AbbVie for the treatment of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. It combines risankizumab (Skyrizi), a humanized monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23A), with ABBV-701 (FG-M701), a fully human monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). By simultaneously inhibiting the IL-23 and TL1A pathways, ABBV-7066 aims to address multiple disease-driving inflammatory and fibrotic pathways to achieve superior clinical and endoscopic efficacy compared to monotherapies. The combination is currently being evaluated in a Phase 2 platform basket study in patients with moderately to severely active Crohn's disease or ulcerative colitis.
- Other names
- Risankizumab + ABBV-701 combinationRisankizumab and ABBV-701Risankizumab/ABBV-701risankizumab + ABBV-701
02
Targets
Beyond the preview
Go deeper on ABBV-7066.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-7066.